114 related articles for article (PubMed ID: 21868783)
1. Incretin-based therapy and the quest for sustained improvements in β-cell health.
Drucker DJ
Diabetes Care; 2011 Sep; 34(9):2133-5. PubMed ID: 21868783
[No Abstract] [Full Text] [Related]
2. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
3. Incretin effects on β-cell function, replication, and mass: the human perspective.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S258-63. PubMed ID: 21525465
[No Abstract] [Full Text] [Related]
4. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Briones M; Bajaj M
Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
[TBL] [Abstract][Full Text] [Related]
5. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
Cvetković RS; Plosker GL
Drugs; 2007; 67(6):935-54. PubMed ID: 17428109
[TBL] [Abstract][Full Text] [Related]
6. Exenatide in combination therapy: small study, big market, and many unanswered questions.
Malozowski S
Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355
[No Abstract] [Full Text] [Related]
7. Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Oriot P; Hermans MP; Selvais P; Buysschaert M; de la Tribonnière X
Ann Endocrinol (Paris); 2011 Jun; 72(3):244-6. PubMed ID: 21652029
[TBL] [Abstract][Full Text] [Related]
8. Treatment of type 2 diabetes mellitus and the incretin system.
Whitehill D
S D Med; 2007 May; 60(5):197, 199. PubMed ID: 17694940
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
10. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
González C; Beruto V; Keller G; Santoro S; Di Girolamo G
Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
[TBL] [Abstract][Full Text] [Related]
11. The role of combination therapy in type 2 diabetes in the post-ACCORD era.
Kuritzky L
Curr Diab Rep; 2012 Jun; 12(3):227-9. PubMed ID: 22528598
[No Abstract] [Full Text] [Related]
12. [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
MMW Fortschr Med; 2009 May; 151(19):50. PubMed ID: 19827447
[No Abstract] [Full Text] [Related]
13. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
[TBL] [Abstract][Full Text] [Related]
15. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Reuter H; Erdmann E
Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
[TBL] [Abstract][Full Text] [Related]
16. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Fabreegas B
Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
[No Abstract] [Full Text] [Related]
17. [Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2].
Musch A; Heinzl S
Med Monatsschr Pharm; 2006 Mar; 29(3):86-9. PubMed ID: 16550880
[No Abstract] [Full Text] [Related]
18. Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics.
McCarty MF
Med Hypotheses; 2007; 69(4):928-32. PubMed ID: 17292559
[TBL] [Abstract][Full Text] [Related]
19. Exenatide.
Keating GM
Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
